Friday, September 22, 2017 10:15 PM ET
Selecta Biosciences (SELB) sees a Significant Insider Sale Slowing Buy Trend Over Last 90 Days
There was a notable sale of shares of Selecta Biosciences by an insider today, as revealed in a form 4 document filed with the SEC. One insider — Amir Nashat, Director — disposed of 147,187 shares in the company having a market value of approximately $2,930,215. There have been 2 insiders with buy/sell transactions in the past 90 days prior to this filing. These trades have resulted in the purchase of 338,791 company shares and the sale of 6,886 company shares over this time period. Adding the most recent activity to this 90-day history indicates insider trades have been net purchases of 184,718 shares and have averaged 164,288 shares per transaction over this time period.
The number of insider buy/sell trades at Selecta Biosciences is above the 266 peer company average over the last 90-day period. The Bio Therapeutic Drugs peer group saw 304 buy/sell trades during this period for an average of 1.1 transactions per company. The number of shares per buy/sell trade for Selecta Biosciences insiders was also higher. Within the peer group there were 8,565,303 shares purchased and 15,518,710 shares sold with company insiders disposing of 22,873 shares on average.
In order to focus on significant insider buying and selling activity, all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers has been eliminated data obtained to evaluate and write this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at email@example.com. Copyright 2017 UpTick Data Technologies. All rights reserved.